The beneficial effect of probiotics as a supplementary treatment in drug-resistant epilepsy: a pilot study
In: Beneficial MicrobesSearch for other papers by M. Gómez-Eguílaz in
Current site
Google Scholar
Search for other papers by J.L. Ramón-Trapero in
Current site
Google Scholar
Search for other papers by L. Pérez-Martínez in
Current site
Google Scholar
Search for other papers by J.R. Blanco in
Current site
Google Scholar
Epilepsy is a neurological disease with high global prevalence. Despite the range of drug-based treatments currently available to control the condition, one in 3 patients experiences epileptic seizures. Therapeutic alternatives for these patients include the ketogenic diet, surgery or the cerebral implantation of neurostimulators; however these are benefits with limits. The target of this study is to find a new complementary treatment for these patients, studying the effectiveness of probiotics for controlling epileptic seizures in patients with drug-resistant epilepsy. A prospective study was designed in which a group of patients with drug-resistant epilepsy was administered a probiotic mixture for 4 months. Patients were assessed before and after taking the probiotics; among other variables, number of seizures and patients’ quality of life (QOLIE-10) were monitored. Levels of cD-14, interleukin 6, and γ-aminobutyric acid were also analysed throughout the study. 45 patients were included in the study. In an intention-to-treat analysis, 28.9% of all patients displayed a greater than 50% reduction in the number of seizures (the parameter required in clinical trials). A significant improvement was also observed in patients’ quality of life. We found that probiotics may be an option for supplementary therapy. Since the use of probiotics is safe, they may contribute to improving seizure control, and therefore quality of life, in patients with drug-resistant epilepsy. The study has been registered in https://clinicaltrials.gov with number NCT03403907.
Purchase
Buy instant access (PDF download and unlimited online access):
Institutional Login
Log in with Open Athens, Shibboleth, or your institutional credentials
Personal login
Log in with your brill.com account
-
Akbari, E., Asemi, Z., Daneshvar Kakhaki, R., Bahmani, F., Kouchaki, E., Tamtaji, O.R., Hamidi, G.A. and Salami, M., 2016. Effect of probiotic supplementation on cognitive function and metabolic status in Alzheimer’s disease: a randomized, double-blind and controlled trial. Frontiers in Aging Neuroscience 8: 256.
'Effect of probiotic supplementation on cognitive function and metabolic status in Alzheimer’s disease: a randomized, double-blind and controlled trial ' () 8 Frontiers in Aging Neuroscience : 256.
-
Alapirtti, T., Rinta, S., Hulkkonen, J., Makinen, R., Keranen, T. and Peltola, J., 2009. Interleukin-6, interleukin-1 receptor antagonist and interleukin-1beta production in patients with focal epilepsy: a video-EEG study. Journal of the Neurological Sciences 280: 94-97.
'Interleukin-6, interleukin-1 receptor antagonist and interleukin-1beta production in patients with focal epilepsy: a video-EEG study ' () 280 Journal of the Neurological Sciences : 94 -97.
-
Anonymous, 2018. Epilepsy. World Health Organization, Geneva, Switzerland. Available at: https://tinyurl.com/yblpkx24.
-
Anu, M., Suresh, K. and Basavanna, P.L., 2016. A cross-sectional study of quality of life among subjects with epilepsy attending a tertiary care hospital. Journal of Clinical and Diagnostic Research 10: OC13-OC15.
'A cross-sectional study of quality of life among subjects with epilepsy attending a tertiary care hospital ' () 10 Journal of Clinical and Diagnostic Research : OC13 -OC15.
-
Bauer, K.C., Huus, K.E. and Finlay, B.B., 2016. Microbes and the mind: emerging hallmarks of the gut microbiota-brain axis. Cellular Microbiology 18: 632-644.
'Microbes and the mind: emerging hallmarks of the gut microbiota-brain axis ' () 18 Cellular Microbiology : 632 -644.
-
Campbell, I.L., Abraham, C.R., Masliah, E., Kemper, P., Inglis, J.D., Oldstone, M.B. and Mucke, L., 1993. Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proceedings of the National Academy of Sciences of the USA 90: 10061-10065.
'Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6 ' () 90 Proceedings of the National Academy of Sciences of the USA : 10061 -10065.
-
Chen, C.H., Lin, C.L. and Kao, C.H., 2015. Irritable bowel syndrome increases the risk of epilepsy: a population-based study. Medicine 94: e1497.
'Irritable bowel syndrome increases the risk of epilepsy: a population-based study ' () 94 Medicine : e1497.
-
Cramer, J.A., Perrine, K., Devinsky, O. and Meador, K., 1996. A brief questionnaire to screen for quality of life in epilepsy: the QOLIE-10. Epilepsia 37: 577-582.
'A brief questionnaire to screen for quality of life in epilepsy: the QOLIE-10 ' () 37 Epilepsia : 577 -582.
-
De Vries, E.E., Van den Munckhof, B., Braun, K.P., Van Royen-Kerkhof, A., De Jager, W. and Jansen, F.E., 2016. Inflammatory mediators in human epilepsy: a systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews 63: 177-190.
'Inflammatory mediators in human epilepsy: a systematic review and meta-analysis ' () 63 Neuroscience and Biobehavioral Reviews : 177 -190.
-
Dickerson, F.B., Stallings, C., Origoni, A., Katsafanas, E., Savage, C.L., Schweinfurth, L.A., Goga, J., Khushalani, S. and Yolken, R.H., 2014. Effect of probiotic supplementation on schizophrenia symptoms and association with gastrointestinal functioning: a randomized, placebo-controlled trial. Primary Care Companion to CNS Disorders 16: 13m01579.
'Effect of probiotic supplementation on schizophrenia symptoms and association with gastrointestinal functioning: a randomized, placebo-controlled trial ' () 16 Primary Care Companion to CNS Disorders : 13m01579.
-
Dinan, T.G. and Cryan, J.F., 2017. The microbiome-gut-brain axis in health and disease. Gastroenterology Clinics of North America 46: 77-89.
'The microbiome-gut-brain axis in health and disease ' () 46 Gastroenterology Clinics of North America : 77 -89.
-
Falip, M., Salas-Puig, X. and Cara, C., 2013. Causes of CNS inflammation and potential targets for anticonvulsants. CNS Drugs 27: 611-623.
'Causes of CNS inflammation and potential targets for anticonvulsants ' () 27 CNS Drugs : 611 -623.
-
Grossi, E., Melli, S., Dunca, D. and Terruzzi, V., 2016. Unexpected improvement in core autism spectrum disorder symptoms after long-term treatment with probiotics. SAGE Open Medical Case Reports 4: 2050313X16666231.
'Unexpected improvement in core autism spectrum disorder symptoms after long-term treatment with probiotics ' () 4 SAGE Open Medical Case Reports .
-
He, Z., Cui, B.T., Zhang, T., Li, P., Long, C.Y., Ji, G.Z. and Zhang, F.M., 2017. Fecal microbiota transplantation cured epilepsy in a case with Crohn’s disease: the first report. World Journal of Gastroenterology 23: 3565-3568.
'Fecal microbiota transplantation cured epilepsy in a case with Crohn’s disease: the first report ' () 23 World Journal of Gastroenterology : 3565 -3568.
-
Hyland, N.P. and Cryan, J.F., 2010. A gut feeling about GABA: focus on GABA(B) receptors. Frontiers in Pharmacology 1: 124.
'A gut feeling about GABA: focus on GABA(B) receptors ' () 1 Frontiers in Pharmacology : 124.
-
Islam, S.U., 2016. Clinical uses of probiotics. Medicine 95: e2658.
'Clinical uses of probiotics ' () 95 Medicine : e2658.
-
Jankowsky, J.L. and Patterson, P.H., 2001. The role of cytokines and growth factors in seizures and their sequelae. Progress in Neurobiology 63: 125-149.
'The role of cytokines and growth factors in seizures and their sequelae ' () 63 Progress in Neurobiology : 125 -149.
-
Kitamura, S., Sugihara, K., Kuwasako, M. and Tatsumi, K., 1997. The role of mammalian intestinal bacteria in the reductive metabolism of zonisamide. Journal of Pharmacy and Pharmacology 49: 253-256.
'The role of mammalian intestinal bacteria in the reductive metabolism of zonisamide ' () 49 Journal of Pharmacy and Pharmacology : 253 -256.
-
Koutsounas, I., Kaltsa, G., Siakavellas, S.I. and Bamias, G., 2015. Markers of bacterial translocation in end-stage liver disease. World Journal of Hepatology 7: 2264-2273.
'Markers of bacterial translocation in end-stage liver disease ' () 7 World Journal of Hepatology : 2264 -2273.
-
Krnjevic, K., 1997. Role of GABA in cerebral cortex. Canadian Journal of Physiology and Pharmacology 75: 439-451.
'Role of GABA in cerebral cortex ' () 75 Canadian Journal of Physiology and Pharmacology : 439 -451.
-
Kwan, P., Arzimanoglou, A., Berg, A.T., Brodie, M.J., Allen Hauser, W., Mathern, G., Moshe, S.L., Perucca, E., Wiebe, S. and French, J., 2010. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 51: 1069-1077.
'Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies ' () 51 Epilepsia : 1069 -1077.
-
Kwan, P. and Brodie, M.J., 2000. Early identification of refractory epilepsy. New England Journal of Medicine 342: 314-319.
'Early identification of refractory epilepsy ' () 342 New England Journal of Medicine : 314 -319.
-
Lehtimaki, K.A., Keranen, T., Huhtala, H., Hurme, M., Ollikainen, J., Honkaniemi, J., Palmio, J. and Peltola, J., 2004. Regulation of IL-6 system in cerebrospinal fluid and serum compartments by seizures: the effect of seizure type and duration. Journal of Neuroimmunology 152: 121-125.
'Regulation of IL-6 system in cerebrospinal fluid and serum compartments by seizures: the effect of seizure type and duration ' () 152 Journal of Neuroimmunology : 121 -125.
-
Lim, K.S., Lotay, N., White, R. and Kwan, P., 2016. Efficacy and safety of retigabine/ezogabine as adjunctive therapy in adult Asian patients with drug-resistant partial-onset seizures: a randomized, placebo-controlled Phase III study. Epilepsy and Behavior 61: 224-230.
'Efficacy and safety of retigabine/ezogabine as adjunctive therapy in adult Asian patients with drug-resistant partial-onset seizures: a randomized, placebo-controlled Phase III study ' () 61 Epilepsy and Behavior : 224 -230.
-
Liu, X., Cao, S. and Zhang, X., 2015. Modulation of gut microbiota-brain axis by probiotics, prebiotics, and diet. Journal of Agricultural and Food Chemistry 63: 7885-7895.
'Modulation of gut microbiota-brain axis by probiotics, prebiotics, and diet ' () 63 Journal of Agricultural and Food Chemistry : 7885 -7895.
-
Noble, A.J. and Marson, A.G., 2016. Which outcomes should we measure in adult epilepsy trials? The views of people with epilepsy and informal carers. Epilepsy and Behavior 59: 105-110.
'Which outcomes should we measure in adult epilepsy trials? ' () 59 Epilepsy and Behavior : 105 -110.
-
Palma, E., Ruffolo, G., Cifelli, P., Roseti, C., Van Vliet, E.A. and Aronica, E., 2017. Modulation of GABAA receptors in the treatment of epilepsy. Current Pharmaceutical Design 23(37): 5563-5568.
'Modulation of GABAA receptors in the treatment of epilepsy ' () 23 Current Pharmaceutical Design : 5563 -5568.
-
Picot, M.C., Baldy-Moulinier, M., Daures, J.P., Dujols, P. and Crespel, A., 2008. The prevalence of epilepsy and pharmacoresistant epilepsy in adults: a population-based study in a Western European country. Epilepsia 49: 1230-1238.
'The prevalence of epilepsy and pharmacoresistant epilepsy in adults: a population-based study in a Western European country ' () 49 Epilepsia : 1230 -1238.
-
Saldana-Cruz, A.M., Sanchez-Corona, J., Marquez de Santiago, D.A., Garcia-Zapien, A.G. and Flores-Martinez, S.E., 2013. Pharmacogenetics and antiepileptic drug metabolism: implication of genetic variants in cytochromes P450. Revista de Neurología 56: 471-479.
'Pharmacogenetics and antiepileptic drug metabolism: implication of genetic variants in cytochromes P450 ' () 56 Revista de Neurología : 471 -479.
-
Sanders, M.E., 2008. Probiotics: definition, sources, selection, and uses. Clinical Infectious Diseases 46, Suppl. 2: S58-61.
'Probiotics: definition, sources, selection, and uses ' () 46 Clinical Infectious Diseases : S58 -61.
-
Serrano-Castro, P.J., Payan-Ortiz, M., Cimadevilla, J.M., Quiroga-Subirana, P. and Fernandez-Perez, J., 2013. Eslicarbazepine acetate in clinical practice. Efficacy and safety results. Revista de Neurología 56: 309-314.
'Eslicarbazepine acetate in clinical practice ' () 56 Revista de Neurología : 309 -314.
-
Severance, E.G. Gressitt, K.L., Stallings, C.R., Origoni, A.E., Khushalani, S., Leweke, F.M., Dickerson, F.B. and Yolken, R.H., 2013. Discordant patterns of bacterial translocation markers and implications for innate immune imbalances in schizophrenia. Schizophrenia Research 148: 130-137.
'Discordant patterns of bacterial translocation markers and implications for innate immune imbalances in schizophrenia ' () 148 Schizophrenia Research : 130 -137.
-
Shi, L.L., Dong, J., Ni, H., Geng, J. and Wu, T., 2017. Felbamate as an add-on therapy for refractory partial epilepsy. Cochrane Database Systems Review 7: CD008295.
'Felbamate as an add-on therapy for refractory partial epilepsy ' () 7 Cochrane Database Systems Review : CD008295.
-
Trinka, E., Steinhoff, B.J., Nikanorova, M. and Brodie, M.J., 2016. Perampanel for focal epilepsy: insights from early clinical experience. Acta Neurologica Scandinavica 133: 160-172.
'Perampanel for focal epilepsy: insights from early clinical experience ' () 133 Acta Neurologica Scandinavica : 160 -172.
-
Viteri, C., Codina, M., Cobaleda, S., Lahuerta, J., Barriga, J., Barrera, S., Morales, M.D. and Grupo de investigadores del estudio de validacion del cuestionario QOLIE-10, 2008. Validation of the Spanish version of the QOLIE-10 quality of life in epilepsy questionnaire. Neurologia 23: 157-167.
'Validation of the Spanish version of the QOLIE-10 quality of life in epilepsy questionnaire ' () 23 Neurologia : 157 -167.
-
Weaver, D.F., 2013. Design of innovative therapeutics for pharmaco-resistant epilepsy: challenges and needs. Epilepsia 54, Suppl. 2: 56-59.
'Design of innovative therapeutics for pharmaco-resistant epilepsy: challenges and needs ' () 54 Epilepsia : 56 -59.
-
Zhu, X., Han, Y., Du, J., Liu, R., Jin, K. and Yi, W., 2017. Microbiota-gut-brain axis and the central nervous system. Oncotarget 8: 53829-53838.
'Microbiota-gut-brain axis and the central nervous system ' () 8 Oncotarget : 53829 -53838.
| All Time | Past 365 days | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 2662 | 968 | 91 |
| Full Text Views | 76 | 13 | 0 |
| PDF Views & Downloads | 124 | 25 | 0 |
The beneficial effect of probiotics as a supplementary treatment in drug-resistant epilepsy: a pilot study
In: Beneficial MicrobesSearch for other papers by M. Gómez-Eguílaz in
Current site
Google Scholar
PubMed
Search for other papers by J.L. Ramón-Trapero in
Current site
Google Scholar
PubMed
Search for other papers by L. Pérez-Martínez in
Current site
Google Scholar
PubMed
Search for other papers by J.R. Blanco in
Current site
Google Scholar
PubMed
Epilepsy is a neurological disease with high global prevalence. Despite the range of drug-based treatments currently available to control the condition, one in 3 patients experiences epileptic seizures. Therapeutic alternatives for these patients include the ketogenic diet, surgery or the cerebral implantation of neurostimulators; however these are benefits with limits. The target of this study is to find a new complementary treatment for these patients, studying the effectiveness of probiotics for controlling epileptic seizures in patients with drug-resistant epilepsy. A prospective study was designed in which a group of patients with drug-resistant epilepsy was administered a probiotic mixture for 4 months. Patients were assessed before and after taking the probiotics; among other variables, number of seizures and patients’ quality of life (QOLIE-10) were monitored. Levels of cD-14, interleukin 6, and γ-aminobutyric acid were also analysed throughout the study. 45 patients were included in the study. In an intention-to-treat analysis, 28.9% of all patients displayed a greater than 50% reduction in the number of seizures (the parameter required in clinical trials). A significant improvement was also observed in patients’ quality of life. We found that probiotics may be an option for supplementary therapy. Since the use of probiotics is safe, they may contribute to improving seizure control, and therefore quality of life, in patients with drug-resistant epilepsy. The study has been registered in https://clinicaltrials.gov with number NCT03403907.
| All Time | Past 365 days | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 2662 | 968 | 91 |
| Full Text Views | 76 | 13 | 0 |
| PDF Views & Downloads | 124 | 25 | 0 |
